Novel preclinical models for treatment of lung cancer
Ramin Massoumi, Professor of Molecular Oncology at Lund University, Sweden, will hold a seminar at CEINGE ( 12.00 h) about "Novel preclinical models for treatment of lung cancer "
A vast majority of drug candidates for cancer treatment fail in clinical trials. One of the main reasons for this failure is models commonly used for drug development. To study and discover effective drugs, more patient-focused models need to be tested in preclinical studies. Two preclinical strategies that have shown compelling results include 3D organoids and the use of patient materials. In our ongoing project, we combine and test different clinically related models in an attempt to identify new drugs against lung cancer, which is one of the deadliest cancers in the world and the therapy options for these patients are limited. We mainly focus on characterizing 3D organoids from primary and metastatic lung adenocarcinoma cells that have been isolated from patients in order to identify new therapies and combination therapies for treatment. Another method in our approach is to monitor tumour behaviour on therapy in real time in vivo. The combined use of genetically characterized cancer cells, drug screening, and advanced molecular techniques for the identification of new anti-cancer drugs together leads to the discovery of innovative strategies and for the treatment of cancer patients.
Host: Mario Capasso, Principal Investigator CEINGE